EP0927711A1 — Adamantane derivatives and process for producing them
Assigned to Daicel Corp · Expires 1999-07-07 · 27y expired
What this patent protects
In the presence of an imide compound (e.g., N-hydroxyphthalimide) shown by the formula (2): wherein R 1 and R 2 independently represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group, a cycloalkyl group; or R 1 and R 2 may bond together to form a double …
USPTO Abstract
In the presence of an imide compound (e.g., N-hydroxyphthalimide) shown by the formula (2): wherein R 1 and R 2 independently represents a hydrogen atom, a halogen atom, an alkyl group, an aryl group, a cycloalkyl group; or R 1 and R 2 may bond together to form a double bond or an aromatic or non-aromatic ring; Y is O or OH and n = 1 to 3; or the imide compound and a co-catalyst (e.g., a transition metal compound), an adamantane derivative having a functional group such as a nitro group, an amino group, a hydroxyl group, a carboxyl group, a hydroxymethyl group and an isocyanato group is oxidized with oxygen. According to the above method, an adamantane derivative having a hydroxyl group together with a functional group such as a nitro group, an amino group, a hydroxyl group, a carboxyl group, a hydroxymethyl group and an isocyanato group is efficiently obtained.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.